@entity396 in the treatment of duodenal XXXX . A multicenter double-blind placebo-controlled study.

@entity1 @entity1066 @entity294 @entity396 @entity158 @entity1443
@entity1 with endoscopically documented duodenal @entity1066 participated in a double-blind, multicenter trial comparing placebo with @entity396 100 micrograms administered q.i.d. for up to four weeks in the treatment of duodenal @entity1066 . Ulcers were examined endoscopically at two weeks and, if not healed, again at four weeks. @entity1443 was permitted for @entity158 relief. At four weeks, of 286 @entity1 admitted to the study, the cumulative healing rate for the 227 evaluable @entity1 was 64.9% for @entity396 and 47.4% for placebo (P = 0.008). @entity396 was also significantly superior to placebo in promoting @entity1066 when all @entity1 entering the study (intent-to-treat cohort) were compared (P = 0.018), and in a modified intent-to-treat cohort consisting of all @entity1 whose final endoscopic results were known (P = 0.005). @entity1066 symptoms were similar in both treatment groups, and most @entity1 in both groups were @entity158 free at the end of the first two weeks of treatment. @entity294 was the most frequently reported adverse experience (8.5% for @entity396 and 3.5% for placebo). This symptom was mild and self-limiting in spite of continued use of @entity396 . We conclude that @entity396 100 micrograms q.i.d. for four weeks is safe and effective in the healing of duodenal @entity1066 .
